Cardiff Oncology Current Ratio 2006-2021 | CRDF

Cardiff Oncology current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cardiff Oncology Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.14B $0.01B 31.20
2021-03-31 $0.13B $0.00B 28.71
2020-12-31 $0.13B $0.01B 21.79
2020-09-30 $0.04B $0.01B 7.02
2020-06-30 $0.03B $0.01B 5.81
2020-03-31 $0.01B $0.01B 2.11
2019-12-31 $0.01B $0.01B 2.37
2019-09-30 $0.01B $0.00B 2.39
2019-06-30 $0.01B $0.00B 3.20
2019-03-31 $0.01B $0.00B 3.76
2018-12-31 $0.01B $0.00B 4.37
2018-09-30 $0.02B $0.00B 6.02
2018-06-30 $0.02B $0.00B 6.10
2018-03-31 $0.01B $0.00B 2.03
2017-12-31 $0.01B $0.00B 2.40
2017-09-30 $0.01B $0.01B 1.68
2017-06-30 $0.01B $0.01B 1.16
2017-03-31 $0.03B $0.01B 3.32
2016-12-31 $0.04B $0.01B 5.00
2016-09-30 $0.05B $0.01B 7.31
2016-06-30 $0.05B $0.01B 4.74
2016-03-31 $0.06B $0.01B 6.02
2015-12-31 $0.07B $0.01B 8.34
2015-09-30 $0.08B $0.01B 10.74
2015-06-30 $0.04B $0.01B 8.47
2015-03-31 $0.04B $0.01B 8.38
2014-12-31 $0.03B $0.00B 6.18
2014-09-30 $0.03B $0.00B 10.11
2014-06-30 $0.04B $0.00B 17.70
2014-03-31 $0.02B $0.00B 11.45
2013-12-31 $0.03B $0.00B 12.98
2013-09-30 $0.03B $0.00B 20.58
2013-06-30 $0.01B $0.00B 5.83
2013-03-31 $0.01B $0.00B 7.95
2012-12-31 $0.01B $0.00B 15.13
2012-09-30 $0.01B $0.00B 10.56
2012-06-30 $0.01B $0.00B 7.64
2012-03-31 $0.00B $0.00B 0.46
2011-12-31 $0.00B $0.00B 0.59
2011-09-30 $0.00B 0.00
2011-06-30 $0.00B 0.00
2011-03-31 $0.00B 0.00
2006-12-31 $0.00B $0.00B 0.98
2006-09-30 $0.00B $0.00B 3.49
2006-06-30 $0.00B $0.00B 10.58
2006-03-31 $0.00B $0.00B 17.13
2005-12-31 $0.01B $0.00B 51.80
2005-09-30 $0.01B $0.00B 25.56
2005-06-30 $0.01B $0.00B 27.94
2005-03-31 $0.00B $0.00B 16.30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.239B $0.000B
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86